


Priv.-Doz. Cornelius Engelmann, MD, PhD
 

---

## 1 | General information

Contact details: Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin Campus Charité Mitte (CCM) and Campus Virchow-Klinikum (CVK)  
Augustenburger Platz 1, 13353 Berlin

Tel.: +49 (0)30 450-630036  
E-mail: cornelius.engelmann@charite.de



Current position: Research Group Leader, Consultant, Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK)

Researcher unique identifier(s): ORCID-ID: 0000-0003-2237-0881

## 2 | Academic education

2018 – 2022 Post-graduate Program, Division of Medicine, University College London, UK  
2000 – 2006 Medical School, University Leipzig (clinical electives: Kantonspital Liestal, Switzerland; Royal Hallamshire Hospital Sheffield, UK)

## 3 | Advanced academic qualifications:

2022 Habilitation “*Prognose bestimmende inflammatorische Marker der Leberzirrhose*”, Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin (Mentor: Frank Tacke)  
2022 PhD thesis “*Synergisms of stem cell mobilization and toll-like receptor 4 inhibition to treat the acute-on-chronic liver failure*”, Institute for Liver and Digestive Health, University College London, UK (Supervisor: Rajiv Jalan)  
2012 MD thesis, Anaesthesia and Intensive Care, “*Propofol versus flunitrazepam for inducing and maintaining sleep in postoperative ICU patients*”, University Hospital Leipzig (Supervisor: Henrik Rüffert)

## 4 | Postgraduate professional career:

Since 2020 Research Group Leader, Consultant, Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin  
2017 – 2020 Senior Research Fellow, Institute for Liver and Digestive Health, University College London, UK  
2017 Senior Clinical Fellow, Royal Free Hospital, London, UK  
2011 – 2016 Internal Medicine Residency, Section Hepatology, University Hospital Leipzig  
2012 German board certification *Internal Medicine*  
2007 – 2011 Internal Medicine Residency, Park-Hospital Leipzig and Heart Centre Leipzig

## 5 | Other:

### Awards/Honors

- International Early Career Investigator Award, The Liver Meeting Boston, AASLD (2019)
- DFG Fellowship (2017 – 2020)
- Young Investigator Bursary Award, International Liver Congress, EASL (2017 – 2020)

### Selected other professional activities:

- Guideline Group Leader “Liver Transplantation” (DGVS) (since 2015)
- Editorial board *Frontiers in Medicine*, *Frontiers in Microbiology*

## 6 | Selected publications:

1. **Engelmann C**, Herber A, Franke A, Bruns T, Reuken P, Schiefke I, Zipprich A, Zeuzem S, Goeser T, Canbay A, Berg C, Trebicka J, Uschner FE, Chang J, Mueller T, Aehling N, Schmelzle M, Splith K, Lammert F, Lange CM, Sarrazin C, Trautwein C, Manns M, Häussinger D, Pfeiffenberger J, Galle PR, Schmiereknecht A, Berg

- T. Granulozyten stimulierender factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). **J Hepatol** 2021; 76(6):1346-1354
2. Kondo T\*, Macdonal S\*, **Engelmann C\***, Habtesion A, Macnaughtan J, Mehta G, Mookerjee RP, Davies N, Pavesi M, Moreau R, Angeli P, Arroyo V, Andreola F, Jalan R. The role of RIPK1 mediated cell death in acute-on-chronic liver failure. **Cell Death Dis** 2021; 13(1):5
  3. Lin S, Araujo C, Hall A, Kumar R, Phillips A, Hassan M, **Engelmann C**, Quaglia A, Jalan R. Prognostic Role of Liver Biopsy in Patients with Severe Indeterminate Acute Hepatitis. **Clin Gastroenterol Hepatol** 2021; Aug 11:S1542-3565(21)00863-6. doi: 10.1016/j.cgh.2021.08.008
  4. Juanola O, Hassan M, Kumar P, Yilmaz B, Keller I, Simillion C, **Engelmann C**, Tacke F, Dufour JF, De Gottardi A, Moghadamrad S. Intestinal microbiota drives cholestasis-undiced specific hepatic gene expression patterns. **Gut Microbes** 2021; 13(1):1-20
  5. **Engelmann C**, Sheikh M, Sharma S, Kondo T, Loeffler-Wirth H, Zheng YB, Novelli S, Hall A, Kerbert AJC, Macnaughtan J, Mookerjee R, Habtesion A, Davies N, Ali T, Gupta S, Andreola F, Jalan R. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liverfailure. **J Hepatol** 2020; 73(1):102-112
  6. **Engelmann C**, Adebayo D, Oria M, De Chiara F, Novelli S, Habtesion A, Davies N, Andreola F, Jalan R. Recombinant Alkaline Phosphatase prevents acute-on-chronic liver failure. **Sci Rep** 2020; 10(1):389
  7. Krohn S, Zeller K, Böhm S, Chatzinotas A, Harms H, Hartmann J, Heidtmann A, Herber A, Kaiser T, Treuheit M, Hoffmeister A, Berg T, **Engelmann C**. Molecular quantification and differentiation of Candida species in biological specimens of patients with liver cirrhosis. **PLoS One** 2018; 13(6):e0197319
  8. **Engelmann C**, Splith K, Krohn S, Herber A, Boehlig A, Boehm S, Pratschke J, Berg T, Schmelzle M. Absolute quantification of microparticles by flow cytometry in ascites of patients with decompensated cirrhosis: a cohort study. **J Transl Med** 2017; 15(1):188
  9. **Engelmann C**, Becker C, Boldt A, Herta T, Boehlig A, Splith K, Schmelzle M, Mueller N, Krohn S, Tautenhahn HM, Bartels M, Sack U, Berg T. Ascites' neutrophil function is significantly impaired in patients with decompensated cirrhosis but can be restored by autologous plasma incubation. **Sci Rep** 2016; 6:37926
  10. **Engelmann C**, Krohn S, Prywerek D, Hartmann J, Herber A, Boehlig A, Zeller K, Boehm S, Berg T. Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival. **Eur J Gastroenterol Hepatol** 2016; 28(11):1285-92

\*contributed equally